Lundbeck

Right

... pants, which, you know, were Biohaven's drug and a number of others, but AbbVie and, and Pfizer are doing incredibly well, and Lundbeck is doing really well with an IV product.

So in terms of revenue, inside of pharma, there's the scientific data.

There's the how do you get it approved, and how much does it cost to get there? And then it's h- what happens when you're commercially there? How do you compete? How do you rebate? How do you co- discount to get really cash to the bottom line to drive the business? So I think that there's aspects of this, you need to understand the history of what's going on in a market.

Prior to that, you had spent most of your career focused on oncology.

So making that pivot to Forum Therapeutics and then Lundbeck, curious on how you made that shift from oncology to neurology.

There's a lot of core functional areas, of course, that are in common as a CEO, as an executive, clinical development that we've talked about, and obviously commercialization like we talked about were key at Millennium.

But curious on how you made that transition to the neurology side of things and what were some of the unique features you had to adjust to?

So I think that courage to continue is also critical.

You need resilience, that you can't be fragile when something doesn't work out the way you thought it was going to.

So you came out of Forum, out of this challenging situation where the drug failed, as we were talking about, and then you joined Lundbeck.

and what ended up becoming a relatively challenging situation at the beginning at Lundbeck there as well.

Let's begin with a significant corporate strategy shift.

Lundbeck has made the decision to relocate its U.S. headquarters to Boston.

This move is strategically designed to establish a global innovation hub that enhances its capabilities in neuroscience and artificial intelligence.

Boston's burgeoning status as a biotech innovation nexus makes it an attractive destination, offering access to a rich ecosystem of research institutions and technological expertise.

Right.

It's a little bit different because this is an established pharmaceutical company, but the Danish biopharmaceutical Lundbeck said Friday morning it's going to leave its U.S. headquarters in Deerfield to relocate to the greater Boston area.

That's because it's planning to build its own global innovation hub and call Boston a leading life sciences ecosystem.

So let's talk about what the state is doing to change that, because some of the biotech industry leaders here are saying that we are building the infrastructure, that the state is providing infrastructures to keep these companies here.

But I do think that the proof in the pudding is going to be what kind of businesses and how much biotech business ends up in the Chicago life science sector.

It'll be an interesting thing to watch.

So what are you working on now? Are you doing more follow-ups on this Lundbeck story of them moving out east?

Yeah, we're trying to look at the effect of Lundbeck moving to Boston and what it really says about what's available to the larger population.

And one of the companies, actually, it doesn't necessarily have to be the big companies.

You know, I heard recently that Lundbeck have done something very innovative recently in terms of, again, trying to push forward in terms of really understanding from a business perspective, how can agentic AI help support better business decisions? And I had read that they're currently looking at, and I suspect that most of the companies will be doing this.

In fact, I know as to how is AI going to really impact our industry as a whole moving forward? And so there are some really interesting partnerships happening out there between tech companies, innovation hubs, and other organizations.

So I think there's many other companies I would look at that are pushing into that space.

And with the support of Reprieve, We took our campaign to the German parliament as well as to the European Union parliament to gain more support.

And we also went to the headquarters of Lundbeck, the lethal injection manufacturer in Denmark, where we were able to convince the Lundbeck executives to write a letter to the governor of Texas, Rick Perry, asking him not to use their product to kill Mark.

And as a result of our visit, Ludwig announced that they would stop supplying this drug to the U.S. prisons carrying out executions.

Yeah.